1 / 1

Stiripentol(Diacomit)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

CAPSULE

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

DIACOMIT (stiripentol) is an anticonvulsant medication prescribed for the treatment of seizures in patients with Dravet syndrome. It is used as an adjunctive therapy alongside clobazam.

Available in both capsule and oral suspension forms, DIACOMIT is particularly important for pediatric patients aged 6 months or older, providing effective management of seizure frequency in individuals who do not respond adequately to other treatments.

Generic name

Stiripentol(Diacomit)

English name

Stiripentol

Alternative Names

Diacomit

Drug prices

Indications

DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome in patients aged 6 months and older, who are already taking clobazam. It is used as an adjunctive therapy and not as a monotherapy. The drug is effective in reducing the frequency of seizures in these patients.

Therapeutic Target

It specifically targets seizure control in patients on clobazam, by enhancing the overall anticonvulsant effect of clobazam.

Active Ingredients

stiripentol

Dosage form

CAPSULE

specifications

Capsule: 250 mg or 500 mg Oral Suspension: 250 mg or 500 mg

Description

DIACOMIT (stiripentol) is an anticonvulsant used to treat Dravet syndrome, a rare and severe form of epilepsy. Stiripentol is used in combination with clobazam and other anticonvulsants to help control seizures that are resistant to other treatments. DIACOMIT works to reduce seizure frequency and improve the patient's quality of life, particularly in pediatric populations. The medication is dispensed in capsules and oral suspension forms for flexibility in administration depending on the patient’s age and swallowing ability.

Dosage and Administration

Dosage: The recommended dosage of DIACOMIT is 50 mg/kg/day, administered in 2 or 3 divided doses.

Administration:

Capsules: Must be swallowed whole with a glass of water during meals. They should not be broken or opened.

Oral Suspension: Mix the powder in a glass of water and take immediately after mixing, also during a meal.

Dose Adjustments: If necessary, the dose may be gradually reduced or discontinued, particularly if adverse effects occur.

CATEGORY NAVIGATION